Supplementary Table 5. Effect of ticagrelor-aspirin compared with clopidogrel-aspirin on safety outcomes stratified by previous antiplatelet therapy among patients with or without ICAS

Outcomes	CA	TA	Crude HR (95% CI)	Adjusted HR (95% CI)*	Adjusted *P* for interaction*
Primary safety outcome					
Severe or moderate bleeding within 90 days†					
ICAS					0.996
Without Pap	4 (0.4)	3 (0.3)	0.75 (0.17–3.34)	0.85 (0.19–3.87)	
With Pap	0 (0)	1 (0.3)	NA	NA	
Non-ICAS					0.995
Without Pap	5 (0.3)	5 (0.3)	1.00 (0.29–3.46)	1.07 (0.31–3.70)	
With Pap	1 (0.5)	0 (0)	NA	NA	
Secondary safety outcome					
Any bleeding within 90 days					
ICAS					0.411
Without Pap	29 (2.8)	41 (4.0)	1.41 (0.88–2.27)	1.38 (0.86–2.23)	
With Pap	6 (3.9)	12 (6.6)	1.73 (0.65–4.62)	1.54 (0.57–4.15)	
Non-ICAS					0.288
Without Pap	36 (2.3)	99 (6.3)	2.82 (1.92–4.13)	2.86 (1.95–4.19)	
With Pap	5 (2.7)	9 (5.0)	1.88 (0.63–5.60)	1.85 (0.58–5.87)	

Values are presented as n (%) unless otherwise indicated.
CA, clopidogrel-aspirin; TA, ticagrelor-aspirin; HR, hazard ratio; CI, confidence interval; ICAS, intracranial arterial stenosis; Pap, previous antiplatelet therapy; TIA, transient ischemic attack.
*Adjusted for age, Han ethnic, sex, body mass index, current smoking status, medical history of hypertension, diabetes, dyslipidemia, myocardial infarction, ischemic stroke, TIA, type of *CYP2C19* loss-of-function allele carrier, and previous lipid-lowering therapy; †Severe or moderate bleeding were defined according to Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) criteria.

Supplementary Table 6. Effect of ticagrelor-aspirin compared with clopidogrel-aspirin on safety outcomes within 1 year stratified by previous antiplatelet therapy among patients with or without ICAS

Outcomes	CA	TA	Crude HR (95% CI)	Adjusted HR (95% CI)*	Adjusted *P* for interaction*
Severe or moderate bleeding†					
ICAS					0.996
Without Pap	7 (0.7)	7 (0.7)	0.99 (0.35–2.82)	1.04 (0.36–2.99)	
With Pap	0 (0.0)	1 (0.6)	NA	NA	
Non-ICAS					0.586
Without Pap	11 (0.7)	7 (0.4)	0.64 (0.25–1.65)	0.68 (0.26–1.75)	
With Pap	1 (0.5)	1 (0.6)	1.01 (0.06–16.16)	1.70 (0.10–29.54)	
Any bleeding					
ICAS					0.350
Without Pap	33 (3.2)	46 (4.5)	1.39 (0.89–2.17)	1.36 (0.87–2.13)	
With Pap	6 (3.9)	12 (6.6)	1.73 (0.65–4.62)	1.54 (0.57–4.15)	
Non-ICAS					0.725
Without Pap	45 (2.8)	105 (2.8)	2.39 (1.69–3.39)	2.44 (1.72–3.45)	
With Pap	5 (2.7)	11 (6.1)	2.30 (0.80–6.61)	2.30 (0.77–6.82)	

Values are presented as n (%) unless otherwise indicated.
CA, clopidogrel-aspirin; TA, ticagrelor-aspirin; HR, hazard ratio; CI, confidence interval; ICAS, intracranial arterial stenosis; Pap, previous antiplatelet therapy; TIA, transient ischemic attack.
*Adjusted for age, Han ethnic, sex, body mass index, current smoking status, medical history of hypertension, diabetes, dyslipidemia, myocardial infarction, ischemic stroke, TIA, type of *CYP2C19* loss-of-function allele carrier, and previous lipid-lowering therapy; †Severe or moderate bleeding were defined according to Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) criteria.

https://doi.org/10.5853/jos.2025.00213